Plain-English translation of NCT07125872 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three treatments for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to previous therapies. The combination includes CD19 t-haNK (a new type of engineered immune cell therapy), N-803 (a medication to boost immune response), and rituximab (an antibody treatment). Researchers want to see if this combination works better than standard treatment alone.
Many people with advanced B-cell lymphoma eventually stop responding to standard chemotherapy and antibody treatments, leaving few good options. This trial is exploring whether this new immune cell therapy, combined with existing treatments, can help people whose cancer has become resistant to earlier therapies.
You likely qualify if…
You likely don't qualify if…
You would first receive preparatory chemotherapy (fludarabine and cyclophosphamide) for three days, then receive the combination treatment every three weeks for up to 12 cycles (36 weeks total). If you respond well, you would continue with maintenance therapy in cycles 7-12. During the first cycle, you would receive phone calls to check on side effects at 6 hours, 24 hours, and 24 hours after each infusion. All participants have regular in-person or phone visits every 12 weeks for monitoring, including blood tests, physical exams, and imaging scans to track how well the treatment is working.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
South Africa
Phase
Testing effectiveness
Sponsor
ImmunityBio, Inc.
Enrollment target
~20 participants
Started
November 2025
Primary completion
May 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Atessa Kiani, MD
ImmunityBio, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.